See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Trade War
Social Media
Donald Trump
Stock Markets
Artificial Intelligence
Trade
Natural Disasters
European Union
Taxes
US Politics
US Economy
Published • loading... • Updated

Dupixent approved as first biologic medicine in Japan for COPD patients - Pharmafile

Summary by pharmafile.com
The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults, whose disease is inadequately controlled by existing therapy. The approval in Japan was based on data from the BOREAS phase 3 study conducted by Sanofi and Regeneron. […] The post Dupixent approved as first biologic medicine in Japan for COPD patients a…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
pharmafile.compharmafile.com

Dupixent approved as first biologic medicine in Japan for COPD patients - Pharmafile

The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults, whose disease is inadequately controlled by existing therapy. The approval in Japan was based on data from the BOREAS phase 3 study conducted by Sanofi and Regeneron. […] The post Dupixent approved as first biologic medicine in Japan for COPD patients a…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmafile.com broke the news in on Wednesday, April 2, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Japan

Japan

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal